Biocodex laboratories join Future4care!

Paris, April 13th. Biocodex, a pioneer and major international player in the field of microbiota and women's health, joins Future4care as a new member.

The arrival of this company, with over 1,600 employees, reinforces the multidisciplinary approach sought by Future4care's founders.

Published on April 11th, 2022 at 10:15 am

For several years now, Biocodex has been investing in start-ups focusing on microbiota, its main area of expertise. The partnership with Future4Care, will enable it to accelerate in digital health and take its place in this ecosystem of excellence.

Future4care and Biocodex share the same convictions, first and foremost that of bringing together the players in the ecosystem to make possible the innovations that will shape tomorrow's healthcare, for the benefit of the patient. By joining the initiative, Biocodex will contribute to the "factory" of solutions that address the issues of sovereignty over healthcare data on a European scale, and the question of how this data should be used.

Nicolas Coudurier, CEO of Biocodex, comments: "We are very honored to be the first pharmaceutical industry partner chosen by the founders of Future4Care. Biocodex will contribute to the tremendous momentum created by this consortium in the service of tomorrow's healthcare. Our industry needs to forge links with players in the personal protection, digital and start-up sectors to address our new challenges, including societal ones, such as, beyond data, prevention. Biocodex is committed to its patients; Biocodex is also committed to its employees, who will benefit from the scheme proposed by Future4Care, which illustrates the acceleration in our transformation."

As a member of the Future4care Selection Committee, Biocodex will play a fundamental role in the ecosystem's governance, in order to :

• Define Future4care's annual themes and illustrations;

• Participate in the choice of selection criteria for selected startups;

• Participate in setting the guidelines for the work of the Future4Care Institute;

• Contribute to the entry of new members.

• Biocodex will also take part in the selection of startups for the various calls for projects launched every six months.

• New members will also benefit from access to Future4care's open innovation platform and a range of acculturation, collaboration and influence services.

• They will also contribute to the work of the Future4care Institute.

For further information, please visit : https://future4care.com

About Future4care

Future4care is the European e-health start-up gas pedal, born of an alliance between Capgemini, Generali, Orange and Sanofi. Its aim is to accelerate the market launch of solutions capable of becoming European e-health champions. Future4care is a unique ecosystem in Europe:

• A 6400m2 space in the heart of Paris, in the 13th district, in the Biopark, to support start-ups in their acceleration phase;

• An open innovation platform to facilitate acculturation, collaboration and influence within the community.

• An Institute, a true knowledge center, offering programs and conferences related to digital health;

• A benchmark label. 

About Biocodex

Biocodex is a French pharmaceutical company founded in 1953 around the development and marketing of the world's first probiotic yeast strain, Saccharomyces boulardii CNCM I-745. Today, Biocodex is developing around three pillars: microbiota, women's health and orphan diseases.

Biocodex employs over 1,600 people and achieved net sales of €418 million in 2021, of which 42% in France and 58% internationally. The Biocodex Group is present in 124 countries, including 20 through its own subsidiaries. Its products are distributed in the rest of the world by partner companies.

Click here to read the interview with Nicolas Coudurier, Managing Director of Biocodex.